In this study, 20 young steers received no beta-agonist (C), 100 animals all received zilpaterol hydrochloride (Z), with 1 group only receiving Z while the other 4 groups received zilpaterol and vitamin D3 at the following levels (IU/animal /day) and durations before slaughter: 7 million for 3 days (3D7M); 7 million for 6 days (6D7M); 7 million for six days with 7 days no supplementation (6D7M7N) and 1 million for 9 days (9D1M). Left carcass sides were electrically stimulated (ES) and the right side not stimulated (NES). Samples were aged for 3 or 14 days post mortem. Parameters included Warner Bratzler shear force (WBSF), myofibril filament length, sarcomere length and calpastatin and calpain enzyme activity.
Introduction
A large portion of South African feedlot cattle are supplemented with a betaagonist to improve feed efficiency and yield. Beta-agonists are known to affect meat tenderness (and other quality traits) negatively due to an increase in calpastatin activity (Koohmaraie, Shackelford, Muggli-Cockett, & Stone, 1991) . Electrical stimulation (ES) could improve meat tenderness by early activation of the calpain system (calciumdependent proteases) (Hwang & Thompson 2001a) . Hope-Jones, Strydom, Frylinck, and Webb (2010) showed that electrical stimulation combined with post mortem aging could improve, but not completely overcome, the negative effect of a beta-agonist on beef loin tenderness.
Various other attempts have been made to activate the calcium-dependent protease system and overcome meat tenderness problems. Wheeler, Koohmaraie, Lansdell, Siragusa, and Miller, (1993) , Kerth, Miller, and Ramsey (1995) and others have used CaCl 2 injections in pre-and post -rigor cuts to activate intra-cellular μ-and mcalpain (Goll, Thompson, Taylor, & Zalewska., 1992; . also showed that CaCl 2 infusion was effective in overcoming beta-agonist induced toughness. In more recent years, supplementation of very high levels of vitamin D 3 over the final days before slaughter has been investigated by Montgomery et al. (2002) , Montgomery, Blanton, et al. (2004) and others to increase plasma calcium levels by stimulating intestinal calcium absorption, mobilizing calcium from bone mineral and increasing renal re-absorption of calcium (as reviewed by Swanek et al., 1999) . Higher blood and muscle calcium would lead to increased activation of the calpains and improved tenderness (Karges, Brooks, Morgan, Gill, Breazile, & Owens, 2001; Montgomery et al., 2002; Montgomery, King, et al., 2004) .
Various studies achieved success with the latter method but reports are not consistent with regards to the level and duration of supplementation as well as the magnitude of the effects. In addition, no studies have reported on vitamin D 3 supplementation to overcome the negative effects of beta-agonists. It is also yet to be verified if the effect of electrical stimulation and vitamin D 3 are additive.
In this trial we investigated various levels and durations of vitamin D 3 supplementation in an attempt to establish the best scenario in terms of cost, safety and efficacy. Our choices were based on previous studies with variable outcomes. Karges, Brooks, Morgan, Gill, Breazile, and Owens (2001) used 6 million IU/animal per day for 4 days and 6 million IU/animal for 6 days resulting in increased blood plasma concentrations and improved beef tenderness. Tipton, King, Paschal, Hale and Savell (2007) , on the other hand, used 3 million IU/animal per day for 5 days and found an increase in calcium levels but no improvement in WBSF. Tendernes did however improve when vitamin D 3 was withdrawn for 7 days after 5 days supplementation. The withdrawal also resulted in lower levels of vitamin D 3 in the liver, but higher levels of calcium were maintained improving tenderness. Montgomery et al. (2002) reported positive effects for tenderness at a relatively low dose (0.5 IU/animal per day) of vitamin D 3 for 9 days without negatively affecting feedlot performance (feed intake) or tissue residues. We have used these scenario's to design our study and also added a short duration of 3 days at 7 million IU/animal per day in an attempt to take advantage of increased calcium levels before homeostasis could restore blood calcium to normal levels.
Materials and methods

Experimental design and feedlot phase
One hundred and twenty Bonsmara steers of approximately 9 months of age were raised on a commercial feedlot diet for 120 days. The animals were divided into six groups (n = 20) so that the average weight and variation was the same for all groups.
The groups represented 6 treatments, namely a control (C), which received the feedlot diet only, while the five remaining groups were supplemented with the beta-agonist, IU/animal /day for 6 days prior to slaughter (6D7M); 7 x 10 6 IU/animal /day for 6 days followed by 7 days of no supplementation prior to slaughter (6D7M7N) and 1 x 10 6 IU/animal /day for 9 days prior to slaughter (9D1M). In abbreviations of treatments D = days, M = million, N = no supplement. Zilpaterol was withdrawn from feed 4 days prior to slaughter. The vitamin D 3 supplement was mixed with maize to increase the volume and supplied as (1 kg) top dressing on the daily supply of the feedlot diet (10 animals per pen). To ensure equal and complete consumption of the supplement, a clean bunk approach was followed, i.e. all feed was consumed before new feed was given each morning. All animals in each pen therefore approached the bunk at the same time and sufficient bunk space was provided so that all animals per pen could have access to feed at the same time.
Slaughter and sampling procedures
The animals were slaughtered at the abattoir of the Animal Production Institute 
Histological measurements
Samples for sarcomere lengths of a fresh LL samples (24 h post mortem), were prepared according the method of Hegarty and Naudé (1970) , by using distilled water instead of Ringer Locke solution (Dreyer, Van Rensburg, Naudé, Gouws, & Stiemie, 1979) . Fifty sarcomeres per sample were measured by means of a video image analyses (VIA) using an Olympus B x 40 system microscope at a 1 000 x magnification equipped with CC12 video camera (Olympus, Tokyo, Japan). AnalySIS Life Science software package (Soft Imaging Systems Gmbh, Münster, Germany) was used to process and quantify measurements.
Myofibril fragment lengths (MFL) of LL aged for 3 and 14 days post mortem were measured by means of VIA. Myofibrils were extracted according to Culler, Parrish, Smith and Cross (1978) as modified by Heinze and Bruggemann (1994) . One hundred myofibril fragments per sample were examined and measured with an Olympus B x 40 system microscope at a 400 x magnification.
Muscle biochemistry
Samples collected for enzyme studies (1 and 24 h post mortem) were snap-frozen in liquid nitrogen and preserved at -70 ºC. Calpastatin, µ-calpain and m-calpain were extracted from 5 g of the LL frozen samples as described by Dransfield (1996) and separated by means of the two-step gradient ion-exchange chromatography-method according to Geesink and Koohmaraie (1999a) . Calpain assays were determined by using azo-casein as substrate according to Dransfield (1996) . The use of azo-casein eliminates the problem of background absorbance of non-specific proteins in the extracts. One unit of calpain activity was defined as an increase in absorbance at 366 nm of 1.0 per h, at 25 °C. One unit of calpastatin activity was defined as the amount that inhibited 1 unit of m-calpain activity. Data were expressed as units per gram of muscle.
Serum calcium and parathyroid analyses
Serum calcium concentrations were analyzed using a colorimetric assay kit (Roche, Mannheim, Germany). Plasma parathyroid hormone levels (PTH) were determined by electrochemiluminescence immunoassay employing a sandwich test principle on a Modular Analytics E 170 (Roche Diagnostic Systems, Nutley , NJ ).
Statistical analyses
Data of WBSF, MFL, calpastatin, µ-calpain and m-calpain activities were subjected to analysis of variance for a split-plot design (GenStat® VSN International, Hemel
Hempstead, UK; Payne, Murray, Harding, Baird, & Soutar, 2007) with the 6 treatment groups (C, Z, 3D1M, 9D1M, 6D7M7N, 6D7M) as whole plots and the two stimulation sub-treatments (ES and NES) and the two ageing periods (3 and 14 days post mortem)
or time of analyses of enzyme activity (1 h and 24 h) as sub-plots. Data of sarcomere length was subjected to a similar analyses, six treatment groups (C, Z, 3D1M, 9D1M, 6D7M7N, 6D7M) as whole plots and only the two stimulation sub-treatments (ES and NES) as sub-plots. Means for the interactions between the whole plot and sub-plots were separated using Fisher's protected t-test least significant difference (LSD) at the 5% level (Snedecor & Cochran, 1980) .
Results
Effect of treatment, stimulation and aging on physical and histological characteristics.
General statistics for the effects of treatment (C, 3D7M, 6D7M, 6D7M7N, 9D1M, Z), stimulation and aging on WBSF, MFL and sarcomere length are presented in Table   1 . Treatment had a significant effect (P < 0.001) on WBSF. Both electrical stimulation (ES) and prolonged aging reduced WBSF significantly (P < 0.001) relative to no stimulation (NES) and aging for 3 days, respectively. A significant interaction (P < 0.001) occurred between treatment and stimulation (P < 0.001), treatment and aging (P < 0.001) and stimulation and aging (P = 0.053) for WBSF. Stimulation had very little effect on the tenderness of the control, but did have a significant effect on all other treatments in particular the zilpaterol group, 6D7M7N and 6D7M (Fig. 1a) . However, the variation (standard deviation) within non-stimulated and 3 days aged treatment groups were higher than within stimulated and 14 days aged groups (data not shown). Furthermore, stimulation also reduced the variation between mean values of all zilpaterol treated groups (zilpaterol and vitamin D 3 treatments). Nevertheless, the control still had a significant (P < 0.05) advantage over other treatments even after 14 days aging (Fig.   1a ).
The control recorded shorter (P < 0.001) MFL's (more myofibrillar degradation) than the other treatment groups under any aging and stimulation scenario (Fig. 1b) .
Aging reduced MFL (P < 0.001) indicating myofibrillar breakdown through proteolyses.
The longer MFL's (or no change) of stimulated samples (Fig. 1b) , indicating less myofibrillar breakdown, were not expected as it contrasts the lower WBSF (more tender meat) of stimulated samples (Fig. 1a) . This suggests the involvement of other tenderizing mechanisms. Neither treatment (P = 0.732) nor stimulation (P = 0.626) had a significant effect on sarcomere length.
Effect of treatment, stimulation and aging on the calcium dependant proteinase system.
General statistics for the effects of treatment (C, 3D7M, 6D7M, 6D7M7N, 9D1M, Z), stimulation and time of measurement on the calcium dependent proteinase system (CDP) are presented in Table 2 . Control samples had lower calpastatin values than zilpaterol and zilpaterol combined with vitamin D 3 samples independent of time of measurement (Fig. 1c) . Stimulation reduced µ-calpain and calpastatin activity measured at 24 h in contrast to 1h measurements ( Fig. 1c and 1d ) (Interaction: P < 0.001).
Available µ-calpain activity was also lower at 24 h compared with 1 h recording, although the effect was much more pronounced for the control and 3D7M than for the other treatments (interaction: P < 0.001; Fig. 1d ). Stimulation tended to increase m-calpain activity at 1 h and reduce activity at 24 h. Table 3 shows the effect of treatment on calcium (Ca) and parathyroid hormone (PTH) levels in the blood. All the vitamin D 3 supplemented groups showed higher blood Ca levels (P < 0.001) than the control and zilpaterol groups with the exception of 6D7M that did not differ from zilpaterol. PTH levels were higher for the control than for all vitamin D 3 treatments and zilpaterol, and zilpaterol alone had higher levels than all vitamin D 3 treatments.
Effect of treatment on blood parameters.
Discussion
The expectation that control samples would be more tender than zilpaterol show through increased action of calpains (possibly lower 24 h activities) and a consequent reduced activity of calpastatin (Doumit & Koohmaraie, 1999) at 24 h as was reported by Swanek et al. (1999; 7 .5 million IU per day for 10 days). In our study, the best positive effect on calpastatin was recorded for 6D7M7N at 1 h, yet in all scenarios the calpastatin activities for vitamin D treatments were still significantly higher than for the control (Fig. 1c) . Mu-calpain showed some variation at 1 h for stimulated samples but apart from a higher activity recorded for 3D7M, the variation in enzyme activity In relation to increased Ca levels, 3D7M and 9D1M showed the best response in tenderness during early stages of aging and when samples were not stimulated, while (2001) reported elevated Ca levels with no response in tenderness improvement similar to our study. Montgomery et al. (2002) showed a positive dose response to levels of vitamin D 3 for plasma Ca but trends for improved WBSF in the opposite direction, i.e. lower supplement levels gave numerically better WBSF results than increasing dosages.
Electrical stimulation (ES) had an overall positive effect on WBSF (lowered values)
which coincided with lower 24 h calpastatin activity in general (Fig. 1c) and a larger reduction in available µ-calpain activity in ES samples between 1 and 24 h (Fig. 1d) . This is in agreement with previous reports by Rosenvold et al. (2007) , Dransfield, Etherington, and Taylor (1992) and Hwang and Thompson (2001a) who found that ES advances the onset of rigor (pH = 6.1, Dransfield et al.,1992) where the activation of µ-calpain is initiated due to the release of Ca + ions which causes proteolysis and tenderization (Ducastaing, Valin, Schollmeyer, & Cross, 1985) . Changes in calpastatin and µ-calpain activities due to ES was accompanied by reduced variation in WBSF among all treatments groups and had the greatest effect on those treatments that were most compromised under NES conditions, such as 6D7M, 6D7M7N and zilpaterol (Fig. 1a) .
Similar results were reported by Ferguson, Jiang, Hearnshaw, Rymill, and Thompson (2000) and Wheeler, Savell, Cross, Lunt, and Smith (1990) when tenderness potential facilitated by the CDP system was compromised by breed (Bos indicus) effect. The negative breed effect was substantially reduced by ES on Bos indicus samples and the total effect was higher than for the non-indicus group. The combined effect of ES and aging in our study reduced the difference between the control and the other treatments to between 1.3 kg (6D7M) and 0.6 kg (3D7M) (Fig. 1a) This agrees with our results that stimulation generally reduce variation in tenderness.
Conclusion
High vitamin D 3 supplement levels does not seem to be a viable option for improving meat tenderness in beta-agonist treated beef. Only a shorter but higher dose (3D7M) and a longer but lower dose (9D1M) of vitamin D 3 showed small but significant improvements in tenderness, under conditions of no electrical stimulation. The benefit of using electrical stimulation on its own should be less costly and show better results on improving beta-agonist treated beef compared to any vitamin D 3 treatment with no stimulation. Furthermore, with electrical stimulation, no added advantage of feeding vitamin D 3 is achieved. Even though stimulation is effective in reducing the effect of a ß-agonist on tenderness, the beta-agonist treated meat remains tougher than non-treated meat and should be avoided if meat quality is the primary objective. Different superscripts in a row shows significant difference (P < 0.05) 
